# Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

> **NCT04116840** · PHASE1 · COMPLETED · sponsor: **Shaanxi Micot Pharmaceutical Technology Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MT1002 for injection

## Key facts

- **NCT ID:** NCT04116840
- **Lead sponsor:** Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-29
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-11-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116840, "Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04116840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*